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Histocompatibility-2 or H-2  ~ is the  major histocompatibility system of the 
mouse  (Mus musculus),  and is probably homologous with the HL-A  system of 
man  (1-3).  It is generally regarded as consisting of two loci, H-2K and H-2D 
(2,  3),  though  there  is some  evidence for  other loci in  the  same chromosome 
region, producing antigens nonreactive or very weakly reactive with H-2 anti- 
bodies,  but  with  effects  on  histocompatibility and/or  the  mixed lymphocyte 
reaction (4).  Since H-2K and H-2D show about 0.5 %  recombination (3)  there 
doubtless  are  other  loci  between  them.  Two  such  loci  have  been  identified. 
Shrefiter and co-workers (5) found, in  this intermediate region, a  locus or loci 
(Ss-Slp) determining the quantity and structure of a serum protein (5-7). This 
has proved to  be a  useful  marker in  crossover studies. Also a  major immune 
response  gene  or  group  of  genes  (It-l)  has  been  located between  H-2K  and 
Ss-Slp  (8). 
Only the separate forms of H-2K and tt-2D and not of the  total H-2 region are 
properly referred to as alleles. Nevertheless, it is convenient to have a  term for the 
separate forms of the chromosome segment as a whole, since, because of the low cross- 
over frequency, it is usually transmitted intact. The term "haplotype" is used in this 
sense in ttL-A  studies, and we shall adopt this usuage here. The H-2K and H-2D loci 
each occur in  several and perhaps many allelic forms, and each allele determines a 
number  of  serologically defined  antigenic  specificities.  These  specificities  can  be 
divided into  private  and  public groups,  the  former  occurring  (with  some  possible 
exceptions) in a  single allelic form of the H-2K or H-2D antigens, the latter occurring 
* This investigation was  supported in part by National Institutes of Health  Research 
Grants AI-10904 and AI-06320 from the National Institute of Allergy  and Infectious Diseases 
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in more than one form (2, 3).  Seven of the known private specificities (H-2.15,  17, 19, 
20, 23, 3l, 33) can be assigned definitely to H-2K, five (H-2.2, 4, 12, 30, 32)  to H-2D. 
The remaining four  (9,  16,  If,  21),  because of the absence of the appropriate cross- 
over, cannot yet be assigned to either locus, quite possibly when the necessary cross- 
overs become available each will split into K  and  D  components. The private H-2 
specificities thus  comprise two mutually exclusive series, one determined by H  2K, 
fine other by H  2D.  They  are generally strong,  especially when  tested  by  lympho- 
cytotoxicity, though there may be some exceptions (2). 
Through  the use of H-2  recombinants of congenic strain Fairs differing one from 
another only at H-2 (9), and of hybrid recipients, it is possible to get donor-recipient 
pairs which  differ by only a  single private specificity, and  to produce  monospecific 
antisera  to  these  specificities. Of  necessity, antisera agains!  the  public specificities 
contain also an antibody against a  private specificity, and sometimes to both  H-2K 
and  H-2D  private speeificities. In some cases,  it is  impossible, with  the haplotypes 
currently  available,  to  selectively eliminate all  the  t?ublic specificities from  strain 
combinations differing by only a single private specificity. 
t)ne possible source of information concerning the H-2K and H-2D loci is studies o~" 
the  alloantigenicity of  their  respective  products.  Several  investigations have  sug- 
gested  that  the  two  antigens  differ in  immunogenicity,  the  products  of  the  H-2D 
locus appearing less immunogenic  than  those  of  the  H-2K  locus.  Thus,  antibodies 
against H-2K private specificities generally show a  higher cytotoxic titer than anti- 
bodies against H-2D private specificities (2),  and  lymphoma  (10)  and skin  (11,  12) 
grafts differing from  the recipient by private or combined private and public H-2K 
specificities are more rapidly rejected than those differing by H-2D specificities. The 
difference in the immune response to H-2K and H-2D antigens was also seen in an 
heterologous  antiserum  made  to  mouse  lymphocytes  (13).  Likewise,  graft-vs.-host 
disease  (11,  14,  15)  and  mixed lymphocyte reactions  (16  18)  are stronger in  strain 
combinations with H-2K differences than in those with H-2D differences, and toler- 
ance induction is easier (11).  Most of these tests have used only a few of the possible 
H-2K and H-2D combinations, and often public specificities have not been excluded. 
A partial reversal of the situation with respect to the relative strengths of H-2K and 
H-2D  may be  seen  in  the  case of marrow  grafts,  where a  postulated H]~-I (hybrid 
histocompatibility) locus at the D  end of the H-2 complex is responsible for the re- 
jection of parental bone marrow grafts made to irradiated F~ recipients (19).  Recent 
evidence, however, indicates that this affect may not be confined to the D end  (20). 
In most of these experiments, multiple H  2 antigenic differences were present 
between donor and recipient. However, when a single H-2K antigenic difference 
was  examined,  specificity H-2.31,  a  number  of factors  affecting the  intensity 
of the ensuing immune response became apparent.  For instance, when a  single 
H-2  antigenic  difference  was  examined,  enhancement  could  be  produced  for 
skin grafts (21) and a gene dose effect demonstrated (22), neither being obtained 
when multiple t]-2 differences were present. We have therefore examined indi- 
vidual  priwtte H-2K  and  1]-2D  antigenic  specificifies to  determine  their role 
in immune responses. Using this model, it is apparent that the K  and D  regions 
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for cell-mediated and humoral responses, and that they differ in their response 
to passive immunological enhancement. 
Materials  and  Methods 
Mice.-  All  mice were  from inbred strains maintained at  the Jackson Laboratory,  Bar 
Harbor, Maine, except that mice of strain B10.S were kindly provided by Dr. J. Stimpfling, 
McLaughlin Laboratories, Great Falls,  Mo.  The standard inbred strains and  the congenic 
resistant  partner  strains  employed  were:  A/WySn,  A.CA,  A.SW,  AKR/J,  AKR.M, 
C57BL/10ScSn,  (hereinafter abbreviated B10),  B10.A,  BI0.A(2R),  B10.A(5R),  B10.AKM, 
B10.BR,  B10.D2/n,  B10.M,  B10.RIII(71NS),  B10.S,  B10.WB,  C3H/HeDiSn,  C3H.SW, 
C3H-II-2 °, DBA/IJ, D1.C, LP.RIII, and SJL/J. The haplotypes of these strains are shown 
in the tables. 13 haplotypes were represented, of which 6 (H-2 a, H-2  h, II-2 ~, H-2 .ia, II-2 m,  and 
H-2 °)  are  known  or  presumed  recombinants.  Strain  A/J  was  sometimes sub3tituted  for 
A/WySn and C57BL/6J  for C57BL/10ScSn. Minor non-H-2  differences between the latter 
two strains have been revealed by tail skin grafts (D.  W. Bailey, personal communication), 
but we have noted little differences using body skin grafts (21). Strain C3H-II-2 ° was originally 
backcrossed to C3H/HeJSt,  but the last two backcrosses were to  C3H/HeDISn.  We shall 
hereafter refer to the strains without the substrain symbols and for strains C57BL/10ScSn 
and C57BL/6J use the abbreviations B10 and B6, respectively. 
Selection of Recipient-Donor  Combinations.--Information  concerning H-2 serotypes and H-2 
recombinants, used in selecting reciplent-donor combinations, came from reviews by Shreffler 
(23) and Klein and Shreffler  (3). We also made use of an unpublished H-2 chart prepared by 
P. Demant, and of the classification  of public and private specificities proposed by Snail et al. 
(2). In so far as possible, recipient-donor  combinations were chosen so that donor and recipient 
differed only by an H-2K private specificity or an II-2D private specificity.  This entailed the 
use of donor and recipient H-2 haplotypes in congenic backgrounds to eliminate non-H-2 dif- 
ferences, and of a recombinant for either the donor or one parent of the recipient, or both, to 
restrict the differences to one end of H-2. It also usually entailed the use of hybrid recipients 
so as to restrict the response to the one chosen specificity,  in a few cases public (presumably 
cross-reacting?) specificities  could  not be  excluded; these are  indicated in  the  tables.  The 
essentially monospeeific private specificity differences thus achieved were: for H-2D, 2, 4, 30, 
32; for H-2K, 15, 17, 23, 31, 33. Combinations differing for private specificities 9, 18,  19 were 
also used. The first two of these have not been localized;  probably they represent the summa- 
tion of D and K  end private specificities.  H-2.19  has been localized  in H-gK "~, its companion 
II-2D ~ specificity is H-2.12,  but because the H-2K qp recombinant haplotype which provided 
the information concerning 19  is not yet available in a  congenie strain,  the combination; 
which we used differed by both 12 and 19. 
Skin Grafts.--Skin  grafts were performed by the method of Billingham and Medawar (24). 
The grafts were considered to be rejected when no viable epithelium remained on macroscopic 
examination of the graft. Second set grafts were placed on the left side of the recipient, 14 
days after rejection of a first set skin graft on the right side.  Male mice,  8  12-wk old,  were 
used in all skin graft experiments, and there were 10-15 mice in each experimental group. The 
statistical analyses were done according the Litchfield (25). 
Production  of Alloantlsera.--Reeipients  for the production of alloantibodies were of mixed 
sexes and, with the exceptions noted below, at least 8-wk old; usually they were F1 hybrids. 
Immunizing injections were given intraperitoneally. The first two injections were thymocytes, 
one young donor per 25 recipients, given 40 days apart. Subsequent injections of cells pooled 
from thymus, spleen, and submaxillary gland, one donor per 10 recipients, given at weekly or 
two weekly intervals, The first bleeding was usually after the fourth injection. The rationale 
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two bleedings on day 7 and 10 after the last injection were alternated with single injections. 
Bleedings were made from the tail. Antisera were stored in a  freezer at --60°C. 
Antisera C-2, C 9, C-17,  C-19, C-30,  C-32, and C-33 were made available at the Jackson 
Laboratory under a National Institutes of Health contract, and were made available through 
the Transplantation Immunology Branch, National Institute of Allergy and Infectious Dis- 
eases, National Institutes of Health, Mice used in the production of these antisera were 5-8-wk 
old at the time of the first injection rather than 8+  wk. On the other hand, the recipients in 
most cases received more than four injections before the first bleeding; the first bleedings of 
C-2  and C-32  were made after  13  injections. These antisera were made approximately 5 yr 
before their use in these tests. AS-377 was approximately 2-yr old when used. All other antisera 
were less than 1-yr old. 
Antisera were also obtained by bleedings on days 10,  15, 20, 25, and 30 following first set 
skin grafts.  Four mice were bled on each of these days and  the sera tested individually by 
the "51Cr cytotoxic method. 
Hemagglutlnating and  Cytotoxic Tests.--Hemagglutination  tests  were  performed  by  the 
PVP method of Stimpfling (27)  with the addition of 0.1% bovine serum albumin (BSA). De- 
tails of the method as we use it are given in the Catalog of Mouse Alloantisera (28). 
Cytotoxic tests were performed using the ~lCr method to measure cell lysis (29).  Spleen 
cells were used as the target and were prepared free of red cells by flushing with Tris-NH4CI 
and incubating at 37°C for 5 mln. 50 #l of aaCr-labeled cells (at a concentration of 10G/ml) were 
mixed with 50  /~1 of antibody diluted in L15  medium  (Microbiological Associates Inc., Be- 
thesda, Md.)  and 50/zl of rabbit complement added. Antiserum titers were calculated using 
semilog probit paper, the titer being defined as the antibody dilutions which caused the release 
of 50%  of the maxinmm ~lCr available for release. The same pool of complement was used 
for all tests, which were performed in duplicate. 
Enhancement Studies.--To  produce passive enhancement of skin grafts, 0.1  ml of the allo- 
antibody pool, reactive with the skin graft donor antigens, was given by the intraperitoneal 
route on days 0, 2, and 4 after the skin grafts. This regimen of antiserum administration had 
previously proved to be effective for the enhancement of skin grafts with an H-2K.31 differ- 
ence (21). Antibody production by mice bearing enhanced grafts was also studied by the atCr 
method described above. 
RESULTS 
First  Set Skin  Graft  Rejections  (Tables  I  and  //).--When  D  region  and  K 
region private specificities were compared, a difference in the time required for 
rejection  was apparent.  D  region specificities produced  slower rejections than 
did  K  region  specificities.  In  recipient-donor combinations in  male m~ce dif- 
fering only by D  region specificities (Table I), median survival times  (MST's) 
ranged from 13.8  4-  1.1  days for H-2.4 to 18.6  4-  1.6 days for H-2.32.  For K 
region differences, the range was 9.3  4- 0.8 days for H-2.J3 to  14.5  4-  1.0  for 
one of several H-2.31  combinations.  Of the D  region specificities,  H-2.4  gave 
rise to the strongest response, while H-2.32 in one donor-recipient combination 
(AKR into AKR.M) gave the weakest. If the antigens are ranked in order of 
immunogenic  potency,  then  at  the  D  region,  the  specificities  are  H-2.4  > 
H-2.30  >  H-2.2  =  H-2.32.  H-2D specificity 32 and H-2K  specificity 31  were 
each  tested  in  a  number of recipient-donor combinations.  Each  showed  con- 
siderable variation. For 32, the MST's ranged from 14.5 -4- 1.3  to 18.6  4-  1.6; 
for 31  they ranged from 9.8  4-  1.0  to  14.5  4-  1.0.  In the discussion we  shall 
consider some of the factors that may be responsible for this variability. I.AN  F.  C.  McKENZIE  AND  GEORGE  D.  SNELL  263 
TABLE  I 
Cytotoxic and Hemagglutinating Antibody Formation and First and Second Set Skin Graft 
Rejection in Recipient-Donor Combinations Differing by Private 
H-ZD Specificities 
Private 
H-2 
specificity 
Cyto-  Hemag- 
Public H-2  Strain and haplotype of  Antiserum  toxic  glutin-  Survival of skin grafts 
anti-  ating  First  Second  specificities  Donor  Recipient*  no.$  body  antibody 
titer  titer  set  set 
H-2.2 
H-2.4 
H-2.30 
H  2.32 
H-2.32 
H-2.32 
MST  ::£ SD 
--  B10.A(2R)  B10.D2 X  A/J  C-2  1/32  1/640  17.8  4-  1.2  9.3  4-  0.7 
1:1-2  h  H-2  d  X  H-2 a 
H-2.41, 42,  B10.A  B10  X  AKR.M  AS-377  1/128-  1/640  13.8  4-  1.2  8.0 4-  0.6 
43,  ?47§  H-2 a  H-2 b X  H-2 m  1/286 
--  B10.AKM  B6 X  A/J  ASM-80  1/128  1/512  15.5  ±  1.0  8.5  4-  0.7 
H-2 m  H-2  a  X  H-2 b 
--  B10.AKM  B10.A X  LD  C-30  1/32  1/1,280  NT  NT 
H-2 m  H-2 a  X  H-2 b 
H-2.13  AKR.M  AKR X  B10  AS-312  1/64  1/320  NT  NT 
H-2 m  H-2 k  X  H-2 b 
--  B10.BR  B10 X  A/J  C-32  1/90  1/1,280  16.0 -4-  1.2  7.8  4-  1.2 
H-2 k  H-2 b X  H  2 a 
--  C3H  C3H.SW X  AS-513  1/64  0  16.8  4-  1.1  8.8  4-  0.6 
A/J 
H-2 k  H-2 a  X  H  2 b 
?H-2.47  B10.BR  B10.A(2R)  X  AS-541  1/90  0  14.5  :t: 1.3  8.2  4-  0.4 
C3H.SW 
H-2 k  H-2b  X  H -2h 
--  C3H  BlO.A(2R) X  AS 485  1/128  0-tr  15.0  4-  1.1  8.5  4-  1.6 
C3H.SW 
H  2 k  H  2 a  X  H-2 b 
?H-2.47  AKR  AKR.M  AS-542  1/64  0  18.6  4-  1.6  9.8  4-  1,8 
H-2 k  H-2 m 
?H-2.47  B10.BR  B10.AKM  AS-543  0  0  15.5  4-  1.1  8.3  4-  0.8 
H_2 k  H-2 m 
* Groups of 15-20 male mice were used as recipients in each experiment. 
:~ The abbreviations used: C, mouse antisera from Catalogue of Mouse Alloantisera; AS, sera produced at The Jackson 
Laboratory; ASM, sera produced in the Department of Surgery, Massachusetts General Hospital by I. McK;  NT, not 
tested;  tr, trace. 
§ The presence of H-2.47 in these sera is uncertain, as the recipient or a  parent of the recipient has not been typed 
for this specificity. 
In the combination for AS-541, B10.BR --~  C3H.SW  X  B10.A(2R),  there  is  also  an  antigenic  difference  of  TL. 
1,2,3, as B10.BR is TL(+),  and the recipients are TL(--).  (37) 
Second Set Skin Graft Rejections  (Tables I  and//).--The  difference between 
D  and K  region antigenic specificities was also observed, but to a lesser extent, 
when second-set skin grafts were performed  10 days after the first grafts were 
rejected.  When  there  was  a  D  region  difference,  second set grafts showed an 
MST of 7.8-9.5  days.  When there was a  K  region difference,  the values were 
6.8-8.2 days. While the H-2D rejections were slower than were those for H-2K, 
the  shortening  in  graft  survival  time  observed  after  priming  with  a  first  set 
skin  graft  was  greater.  Second  set  grafts  performed  in  the  presence  of  a  D 
region  antigenic  difference were rejected  up  to 9  days earlier  than  a  first  set 
graft;  when  there  was  a  K  region  difference  grafts  were  rejected  2-4  days 
earlier. 
Skin Graft Rejection in Hyperimmunized Mice.--The  F1 hybrid female mice 264  IMMUNOGENICITY  AND  ENIIANCEABILITY OF  H-2  ANTIGENS 
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that were used to produce antibody, and which had therefore received 13-15 
injections of donor lymphoid cells, were used as recipients for donor skin grafts. 
In all cases,  irrespective of the antigens involved, the grafts were rejected be- 
tween 6.5 and 8.0 days. No graft prolongation or active enhancement was seen, 
and no difference in the rate of rejection for K or D region antigenic differences. 
Cytotoxic and Hemagglutinating Antibody Formation after Immunizations with 
Lymphoid Cells (Tables I  and II).--D region antigens gave lower titers of cyto- 
toxic antibodies than K  region antigens. As with the skin graft survival, H-2.4 
appeared to be the most immunogenic D region specificity and H-2.2 the least. 
With  the  possible  exceptions  of  AS-377  (anti-H-2.4),  cytotoxic titers  to  D 
region antigens were not greater than 1/128. AS-543, a (B10.AKM anti-B10.BR) 
antiserum did not form a detectable cytotoxic anti-H-2.32 antibody, even after 
15 injections of lymphoid cells.  This is possibly an example of an Ir (immune 
response)  effect conferred by the  C57BL/10 genetic background  (McKenzie 
and Snell, unpublished data). Five other anti-32 antisera gave cytotoxic titers 
ranging from 1/~4 to 1/~28. 
At the K  region, cytotoxic antibody titers ranged from ~2  to ]/~,04s.  Only 
4 of 16 titers were ~/~2s or less,  hence overlapping the D  region range. As we 
shall point out in the Discussion, some of the variability was probably due to 
identifiable factors other than the properties of the antigen itself. 
The hemagglutinating titers were difficult to interpret, as several H-2 speci- 
ficities, notably 31, 32, and 33, do not usually lead to hemagglutinating activity. 
However, several late bleeds after prolonged immunization contained antibody 
to H-2.33 (C-32 and AS-485). In addition, when H-2.17 was made in one com- 
bination (AS-545), no hemagglutinating antibody was detected. The difference 
between H-2D and H-ZK region specificities in the titers of cytotoxic antibody 
and in skin graft survival was not reflected in  the titers for hemagglutinating 
antibodies.  Antigenic  specificities from both regions led to  hemagglutinating 
antibody titers of 0 to 1/~,2s0. 
Cytotoxic  Antibody  Formation after  a First Set Skin Graft  (Table///).--The 
humoral response engendered by a  skin graft was much more pronounced for 
H-2K than for H-bD differences. Cytotoxic antibodies were found consistently 
on day  10,  the  approximate time of rejection of skin  grafts where K  region 
specificities were present. The titers subsequently rose to a maximum of 1/~4 to 
1/~56 on days 15  20, and  then began to fall. By contrast, when there was an 
antigenic difference of a  D  region specificity, no cytotoxic antibody was  de- 
tectable in six of nine combinations. In the other three, titers of }~ to 1/~ were 
present on days 10 or 15.  No  tests were run for hemagglutinating antibodies 
in these sera. Clearly, skin grafts performed when there is an H-bD specificity 
difference give rise to relatively poor humoral as well as poor cellular immune 
responses. 
Enhancement of Skin  Grafts by the Passive Administration  of AIloantibody  to 
the Private H-2K and H-2D Specificities  (Tables IV and  V).--Althongh H-2K IAN  F.  C.  MCKENZIE  AND  GEORGE  D.  SNELL  267 
TABLE III 
Cytotoxic Antibody Titers Formed after a Skin Graft in Alloantibody Treated and Untreated Mice 
H-2 
Region  specificity  Donor  Recipient 
Antibody  Cytotoxic antibody  titer* 
treatment  10  15  20  25  30 
H-2D 
H-2K 
day 
H-2.2  B10.A(2R)  B10.D2  X  A/J  None  0  0  0  0  0 
C-2  0  0  0  0  0 
H-2.4  B10.A  B10 X  AKR.M  None  0  I/8  0  0  0 
AS-377  1/8  0  w§  0  0 
H-2.30  B10.RIII  B6  X  A/J  None  0  0  0  0  0 
(71NS)  ASM-80  0  0  0  0  0 
H-2.32  B10.BR  B10 X  A/J  None  0  0  0  0  0 
C-32  0  0  0  0  0 
Br-2.32  C3H/DiSn  C3H.SW X  None  0  0  0  0  0 
A/J  AS-513  1/4  0  0  0  0 
H-2.32  BlO.BR  B10.A(2R)  X  None  0  0  0  0  0 
C3H.SW  AS-541  0  0  0  0  0 
H-2.32  C3H/DiSn  BI0.A(2R)  X  None  0  0  0  0  0 
C3H.SW  AS-485  1/6  0  0  0  0 
H-2.32  AKR/J  AKR.M  None  0  0  0  0  0 
AS-452  0  0  0  0  0 
H-2.32  B10.BR  B10.AKM  None  0  0  0  0  0 
AS-543  0  0  0  0  0 
H-2.9  B10.M  B10.D2  X  None  1/16  1/128  1/128  NT  1/64 
A.SW  09  0  1/16  1/64  1/128  1/64 
17-2.!5  B10.WB  B10.A(2R)  X  None  1/8  1/64  1/128  1/128  NT 
A.CA  AS-537  1/6  0  1/32  1/64  1/128 
H-2.17  DBA/1J  D1.C X  None  1/64  1/64  1/64  1/64  NT 
B10.AKM  C-17  0  0  1/16  1/64  1/64 
1t-2.18  B10.RIII  B10 X  A/J  None  1/32  1/64  1/128  1/64  NT 
(71NS)  ASM-81  1/8  0  1/16  1/128  NT 
H-2.18  B10.RIII  B10.D2  X  None  w  1/64  NT  NT 
(7INS)  DBA/1J  AS-512  0  0  1/8  NT  NT 
H-2.31  C3H.H-2  °  C3H/DiSn  X  None  1/4  1/64  1/128  1/128  NT 
B10  AS-561  0  1/16  1/64  1/236  1/128 
H-2.31  B10.D2  B10 X  A/J  None  0  1/64  1/128  1/256  1/256 
AS-539  1/8  0  1/64  1/128  1/128 
H-2.33  B10.A(5R)  B10.D2  X  None  w  1/64  1/256  1/128  NT 
A/J  033  1/8  0  0  1/64  1/128 
* Cytotoxic  antibody  was measured by the  51Cr cytotoxic  test.  The  titers are  the approximate  means  ob- 
tained from testing, separately,  the serum obtained  from four mice. 
Alloantibody reactive with donor antigens was given 0.1 ml on days 0, 2, and 4 after skin grafting to a  group 
of 10-15  mice, the other group received no serum. Bleedings were performed on days 10,  15, 20,  25, and 30, after 
the graft 
§ W, weak. 
specificities  appear to be more immunogenic for  both  cell-mediated and  hu- 
moral immunities than are H-2D specificities,  enhancement of skin grafts was 
far greater in  the presence of H-2K  than of H-2D  region differences. Thus, 
graft prolongation of 2.4 to 6.7 days occurred with K  region specificities,  but 
of only 0.2 to 1.5 days with D region specificities.  This is illustrated in Fig. 1, 
which shows the survival time of skin grafts in mice, both with and without 
alloantibody administration, for the two Hi26 private specificities  H-2D.2 and 
H-2K.33.  The skin grafts bearing H-2.33  (H-2K region) from the B10.A(5R) 
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TABLE IV 
Passive  Enhancement  of Skin Gra[ts in Mice Differing  by Single  Private 
Spect~icilies  at  the  H-2D  Locus 
1I 2  Antibody  Skin graft  Prol(m- 
Specificity  Donor  Recipient  treatment*  survival  gation 
MST -1= SD, days  days" 
11-2.2  B10.A(2R)  B10D2  X  A/J  None  17.8  ±  1.2  0.4 
C-2  18.2  4-  1.3 
H-2.4  B10.A  B10 X  AKR.M  None  13.8  4-  1.1  0.7 
AS-377  14.5  4-  1.1 
H2.30  BI0.AKM  B10 >  A/J  None  15.5  4-  1.1  0.7 
ASM-80  16.2  4-  1.2 
H-2.32  BI0.BR  B10 X  A/J  None  16.0  4-  1.2  0.8 
C-32  16.8  4-  1.4 
II 2.32  C3H/DiSn  C3H.SW  X  None  16.8  4-  1.1  1.5 
ALl  AS-513  18.3  4-  1.1 
II-2.32  BI0.BR  B10.A(2R)  X  None  14.5  4-  1,3  0.2 
C3H.SW  AS-541  14.7  4-  1.2 
H-2.32  C3H/1)iSn  C3H.SW  X  None  15.0  4-  1,1  1.0 
B10.A(2R)  AS-485  16.0  4-  1.1 
H-2.32  AKR/J  AKR.M  None  18.6  4-  1.6  0.3 
AS-542  18.9  4-  1,9 
H-2.32  B10.BR  B10.AKM  None  15.9  4-  1,1  0.7 
AS-543  16.8  4-  1.1 
* Alloantibody given 0.l ml i.p. on days 0, 2, and 3, after skin graft. 
from the B10.A(2R) donor, bul this early rejection could be delayed by passively 
administered antiserum to H-2.33.  The graft bearing the weaker H-2.2  (H-2D 
region) showed a  late rejection, but this was scarcely affected by passively ad- 
ministered anti-H-2.2.  The degree of enhanceraent was similar for all K  region 
specificities and was similar to that previously reported, for the K  region speci- 
ficity H-2.3I  (21). 
Although the earlier studies did not suggest that prolonged dosage affected 
the degree of enhancement  attained  (21), it still seemed possible that the lack 
of enhancement for H-2D region antigens was due to the long interval between 
the last dose of antibody (4 days after the skin was grafted) and graft rejection, 
with  a  consequent  disappearance of antibody.  For example, for  the D  region 
specificity H-2.2,  14 days elapsed between  the last dose of antibody and  first 
set  skin  graft  rejection,  whereas  for  K  region  specificity H-2.31  the  elapsed 
time was only 6  days. To  exclude a  possible insufficiency of antibody, 0.2  ml 
of C-32, anti-H-2.32,  was given every second day until graft rejection occurred 
in the combination B10,BR into (B10 X  A)F1. Enhancement was not increased, 
the  grafts  being  rejected  at  the  same  time  as  with  the  standard  three-dose 
regimen.  Similarly, a  dose of 0.5  ml  on days 0,  2,  and  4  had  no  effect on  the 
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TABLE  V 
Passive Enhancement of Skin Grafts in Mice Differing by Single Private 
Speciflcities  at  the  H-2K  Locus 
H  2K  Donor  Recipient  Antibody  Skin graft  Prolon- 
Specificity  treatment*  survival  gation 
MST 4-  days 
SD, days 
H-2.9  B10.M  BI0.D2 X  A.SW  0  10.2 4-  1.2  5.1 
C  9  15.3 ±  1.4 
H-2.9  B10.M  B10.D2 X  SJL/J  0  10.8 4-  1.1  3.4 
AS-544  14.2 4-  1.2 
H 3.15  B10.WB  A.CA X  B10.A(2R)  0  9.8  4-  1.1  4.8 
AS  537  14.6 ±  1.2 
H-2.17  DBA/1J  DI.C X  AKR.M  0  10.5 4-  0.i  4.0 
AS-545  14.5 4-  0.1 
H 2.17  DBA/1J  D1.C  X  B10.AKM  0  12.5 4-  1.0  4.0 
C  17  16.5 ±  1.2 
1I-2.18  B10.RIII(71NS)  B10 X  A/J  0  9.6 4-  1.1  4.2 
B10.RIII(71NS)  B10 X  A/J  ASM 81  13.8 4-  1.1 
BI0.RIII(71NS)  B10 X  A/J  AS 381  12.5 -4-  0.8  3.1 
BI0.RIII(71NS)  B10D2 X  DBA/1J  AS-538  12.0 =t_  0.5  2.4 
H-2.19  A.SW  A.CA X  B10.A  0  9.8  4-  1.2  4.4 
C  19  14.2 4-  1.2 
H  2.19  B10.S  A.CA X  B10.A  0  10.3 4-  1.2  4.7 
C  19  15.0 4-  1.5 
H 2.23  B10.A  B10.RIII(71NS) X  PL/J  0  11.5 :4-  1.1  3.7 
AS-512  15.2 4-  1.1 
H-2.31  B10.D2  BI0 X  A/J  0  10.3 ±  1.3  6.7 
AS 539  17.0 4-  1.1 
H-2.3l  B10.D2  B6 X  A/J  0  10.8 :=b  1.4  5.2 
AS 539  16.0 4-  1.5 
H  2.31  B10.D2  B10.A  0  11.8 4-  1.1  4.2 
AS-539  16.0 4-  1.2 
H-2.31  B10.D2  B10 X  BI0.A  0  14.5 :b  1.1  2.3 
AS 539  16.8 4-  1.5 
H-2.3l  D1.C  BI0.A X  DBA/1J  0  12.2 ±  1.1  4.2 
AS 562  16.4 4-  1.2 
II 2.31  B10.D2  B10.A X  DBA/1J  0  11.4 :i: 1.0  4.2 
AS-563  16.4 4-  1.2 
H-2.31  C3H.H-2  °  C3H/DiSn X  B10  0  9.8  4-  1.0  4.8 
AS 561  14.6 4-  1.0 
H-2.33  B10.A(5R)  B10D2 X  A  0  9.3  4-  0.8  6.0 
C-33  15.3 4-  1.4 
* Alloantibody  given  0.1  ml  i.p.  on  days  0,  2,  and  4. 
Although the specificity of the enhancement of skin grafts had been demon- 
strated in an earlier study, a check was included here. A group of 10 (B6 X  A)F1 
mice  received  a  B10.BR  skin  graft  (an  antigenic difference  of H-2D.32) and 
0.1 ml of anti-H-2K.31, intraperitoneally, on days 0, 2, and 4. The grafts were 
rejected in normal fashion with no prolongation. 
Antibody-Mediated Suppression of Alloantibody Formation (Table IH).--For 
K  region antigens,  the administration of passive  antibody on days 0,  2,  and 4 
after skin grafting delayed the appearance of cytotoxic antibody for 5-15 days. 
However,  in most  cases,  antibody appeared  approximately  at  the same  time 
that the graft was rejected. In mice receiving antibody passively, antibody pre- 270  IMMUNOGENICITY  AND  ENHANCEABILITY  OF  H-2  ANTIGENS 
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FIO.  1.  The MST for skin grafts is shown for the two private antigens of the H-2  b haplo- 
type: 1[-2.33  (H-2K) and H-22 (H-2D). In both cases, male (B10.D2  X  A)FI recipients were 
used and received a B10.A(2R) graft (for H-2.2) or a B10.A(5R) graft (for H-2.33). The basic 
differences in the immunogenicity of tile skin graft is illustrated when the H-2.2 graft is re- 
jected later  than the H-2.33 graft. By contrast, enhancement could be produced for H-2.33 
but not with H-2.2. 
sumed to be residual antibody, was still detectable on day 10, but absent on 
day 15. The studies of D  region specificities could reveal no suppressive effect, 
there being little antibody formed even in untreated mice. 
DISCUSSION 
The H-2 system of the mouse is generally regarded as consisting of two allo- 
antigen-determining loci, H-2K and H-2D. By appropriate choices of recipient- 
donor combinations, it has been possible to stud}- various manifestations of the 
immune response where recipient and donor differed by single, private H-2K 
or single, private H-2D specificities. The responses measured included the re- 
jection  tinles  of  first  and  second-set  skin  grafts,  the  lymphocytotoxic and 
hemagglutinating  antibody  responses  engendered  by  multiple  injections  of 
donor tissue, the lymphocytotoxic response engendered by first-set skin grafts, 
and the degree to which immunological enhancement could be induced by the 
passive transfer of alloantibody. By all tests except the production of heinagglu- 
tinating antibody, where no K-D difference was observed, the K  antigen ap- 
peared to be stronger than the D antigen. Thus the MST of grafts ranged from 
9.3  to 14.5 days for K  end differences, and from 13.8 to 18.6 for D  end differ- 
ences. On the other hand, enhancement was much greater for the stronger K 
end differences than for the weaker D end differences. For the former, it ranged 
from 2.4 to 6.7 day's,  for the latter from 0.2  to 1.5 days. IAN  t~.  C.  McKENZIE  AND  GEORGE  D.  SNELL  271 
Differences in the immunogenic strength of the H-2K and H-2D alloantigens 
similar to  those  reported here,  have  been  observed also with  heart  (30)  and 
kidney (31)  transplants. 
There was considerable consistency in both  the H-2K  and H-2D responses. 
Nevertheless,  there is reason  to believe that  there were in both sets of tests a 
number  of  identifiable variables  which,  if  they  could  have  been  eliminated, 
would have made  the results at each  locus more uniform  and  the  differences 
between  the loci even more striking. Some of these variables are as follows. 
The  Tla  locus is  closely linked with H-2,  and  some 11-2 congenic stocks conse- 
quently differ at Tla as well as H-2. While Tla is primarily demonstrable through the 
cytotoxicity of thymic lymphocytes, it has recently been shown that it causes, or is 
associated with, a  weak histocompatibility (32,  33). In our D  end 11-2.32 combina- 
tion, B10.BR into B10.A(2R)  X  C3H.SW (Table I), the donor was Tla-1,  2, 3 and the 
recipient Tla-negative. The MST for this combination, 14.5 ~  1.3 days, was the second 
lowest. In our two 11-2.9 combinations (Table II), the donor was probably TIa-1, 2, 3, 
the  recipients  Tla-2/Tla-negative.  The  effect  of  Tla  on  histocompatibility in  this 
particular combination has not been determined. The MST's were within the normal 
range. 
There are a  number of H-2 private specificities which include two or three public 
specificities. These can be interpreted as the manifestation of cross-reactions. Thus 
anti-H-2.25 may be an antibody reacting with both H-2.1g and 1t-2.23.  If there are 
indeed such cross-reactions, one might expect that strain combinations in which the 
antigens of recipient and  donor are cross-reacting, and hence antigenically related, 
will give relatively weak immune responses. The two tt-2.23 combinations (Table lI) 
are a possible example, since H-2.1g was present in the recipient. The first of the two 
combinations,  B10.A  into  B10.RIII(71NS)  N  PL/J,  moreover, probably blocks a 
second  cross-reaction.  Strain  PL/J  (H-2  ~)  has  been  shown  to  react  with  anti-23 
antisera (34, no symbol has been assigned). Not surprisingly, this combination showed 
both a slow rejection for a K  end difference (MST 11.5  ±  1.1) and a particularly weak 
cytotoxic titer (1/70). The second combination, sharing only 11-2.25, gave a somewhat 
weak antibody (titer 1/256)  but a  normal MST  (10.2  4- 0.8). It is also noteworthy 
that H-2.4, which appeared to be the strongest of all D  end specificities, was studied 
in a combination which failed to exclude three or four potential cross-reactions, though 
this may merely mean  that  one  of the determinants of antigenic "strength"  is the 
capacity to trigger a diversity of antigen-reactive cell clones. In one 11-2.18 combina- 
tion, B10.RIII (71NS) into B10  X  A/J, in which cross-reacting antibody 11-2.25 was 
blocked,  the  immune  responses appeared particularly strong.  But H-2.1S  is excep- 
tional in that it is presumably the sum of both K  and D private specificities. 
It has been reported that DBA/1 and DBA/1 hybrids mount a particularly weak 
resistance to skin and  tumor allografts (35,  46).  In five cases involving specificities 
H-2.17,  H-2.1g,  and H-2.31  (Table II), DBA/1  or a  DBA/1  congenic line was one 
parent of the recipient. In four of these five cases the other parent was B10 or a B10 
congenic. These four cases showed relatively slow graft rejection for K  end combina- 
tions  (MST's of  12.5,  11.2,  12.2,  and  11.4)  and relatively poor antibody production 
(cytotoxic titers of 1/512,  1/300,  1/32,  1/32). In the fifth combination, DBA/1  into 
D1.C  X  AKR.M,  graft  rejection and  cytotoxic antibody production were  slightly 
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In four of the donor-recipient combinations in Tables I  and II, the recipients were 
either nonhybrids or a  hybrid between  congenie partners.  With  the  one  exception 
B 10.BR into B10.AKM, where graft rejection was rapid, these combinations showed 
slow rejections and low antibody titers. This could mean that absence of hybrid vigor 
weakens  the immune  response. Alternatively, or in addition,  the  unhybridized B10 
genetic background may be unfavorable to some H-2 immune responses. 
As noted under Methods, the seven "C" antisera were produced with a  somewhat 
different immunization schedule than the "AS" or "ASM" antisera, and were much 
older when used. The cytotoxic titers were generally somewhat low. 
H-2 is the prototype of a  "strong" histocompatibility "locus" (37).  Now that it is 
known to consist of linked loci, which can be studied separately, the question of its 
strength is open to reexamination. H-2K  still appears as a  uniquely strong locus, in 
terms of skin graft rejections, almost as strong as the undivided H-2 complex. It is 
very clear from this study that H-2D is somewhat weaker. But compared with non- 
H-2 loci, for which the shortest MST's are of the order of 20-25  days (38),  it still 
appears as relatively strong. 
H-2K  and H-2D  are unique  among histocompatibility loci in the ease with 
which  they  are  demonstrated  by  serological  as well  as  transplantation  tech- 
niques. They are closely linked and perhaps the product of reduplication of a 
single, ancestral locus (34, 39). Antisera made against the antigen of one some- 
times cross-react with  the  antigen  of the other  (3,  40,  Snell and  Cherry,  un- 
published  data).  The  H-2K  and  H-2D  antigens  show  considerable  chemical 
similarity (41).  With all these indications of similarity, why is one locus asso- 
ciated with stronger immune responses than the other? 
It is possible that the difference is in part an artifact, the product of  unfavorable 
immune response genes in some or all of the combinations in which H-2D  has been 
studied. Lilly et al. (42) showed that B10 and some of its congenic partner strains are 
poor responders to D  end specificity It-2.2, and Stimpfling and Durham  (43) demon- 
strated a role of the H-2 region itself on the response to H-2.2.  This may apply also to 
other D  end specificities (44,  McKenzie, Cherry, and Snell, unpublished data).  As a 
case in point, AS-543, B10.AKM anti-B10.BR, did not contain the anticipated anti-32. 
H-2D has usually been studied in combinations in which B10 and  its congenics are 
present. But when the best combinations which we have encountered for the produc- 
tion of anti-H-2D are compared with the best combinations for the production of H- 
2K, the difference still remains substantial. 
Despite the demonstrable chemical similarities of H-2K and H-2D, it is pos- 
sible that undetected chemical differences account for the differences in anti- 
genic strength.  But  this is no direct evidence in  support of such  a  possibility. 
The I-I-2 complex plays a major role in the mixed lymphocyte reactions  (45, 
46).  Lymphocytes differing at  H-2  regularly show  stimulation  in  mixed  cul- 
tures,  whereas,  with  a  few  major  exceptions,  non-//-2  combinations  do  not 
stimulate or stimulate weakly. Most of the mixed lymphocyte reactivity of the 
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47, 48).  Originally,  it was assumed  that  the 11-2 loci themselves  were the re- 
sponsible  agents,  but  recent  evidence,  based on the use of certain  critical  re- 
combinants, indicates that the effect maybe due primarily to other components 
of the complex  (4,  47).  A  major part  of the activity seems to be due  to Ir-1, 
or some locus not now separable from it, but there is a weaker center of activity 
near to but independent of H-2D. 
The critical recombinant haplotypes with respect to K  end mixed lymphocyte 
reactivity  are H_2y-~J and  H-2  y-s~. These  are  identical  with  respect  to H-2K 
and H-2D but, as a result of recombinations at the extreme left and right ends, 
respectively, of the complex, differ at It-1 and SsSlp. H-2  ~-Kzj arose from a rare 
crossover between  H-2K  and It-l,  thus providing a  source of information  as 
to the effect of these loci separately.  These particular recombinant haplotypes 
were not used in  our tests. 
Another example of unexplained  reactivity associated  with  the K  end  of H-2 is 
provided by the H-2 mutant, H-2  ~a (49). Skin grafts exchanged between  the original 
and the mutant haplotypes are strongly rejected, but numerous tests failed to reveal 
any serological  difference.  F1 tests with appropriate recombinant haplotypes localized 
the effect at  the K  end.  Whether  the  change is at H-2K  itself,  or at  some closely 
linked, heretofore undetected histocompatibility locus is unknown. 
There are thus, at the K end of the It-2 region, known or postulated loci, other than 
H-2K itself, which can engender immune or at least blastogenic responses. This makes 
it tempting to assume that part of the unusual strength of H-2K as compared to H-2D 
is due to these companion loci. From what is known of these loci, it can plausibly be 
supposed that they contribute part of the potential for rapid graft rejection associated 
with the K  end. However, since it is a primary characteristic of these loci that they 
are not demonstrable serologically,  they donot serve to explain the strong serological 
responses associated with the K  end. 
Perhaps the most surprising property of the K  end revealed in these studies 
is the relative success of the enhancement of graft survival by passively trans- 
ferred antibody. Graft prolongation was generally less than 1 day in the D  end 
tests, generally more than 4 days in the K  end tests. 
The poor response of H-2D seems not to be due to some intrinsic  resistance 
of the  H-2D  alloantigenic  specificities  to immunosuppression.  Demant  et  al. 
(50)  have shown  that  rabbit  antimouse lymphocyte serum more than doubles 
the survival of skin grafts with an H-2D difference.  Grafts with an H-2K dif- 
ference responded less effectively. Also, host irradiation can substantially pro- 
long the survival of grafts across the H-2D barrier  (51). 
If the K  end loci other than H-2K do not determine antibody-inducing anti- 
gens,  they cannot provide an explanation  of the efficiency of K  end enhance- 
ment. Another possibility is that K  end antibodies enhanced better simply be- 
cause  they were stronger.  However,  there was little  correlation  between  anti- 
body titer and enhancement.  Thus K  end antibody AS-563, anti-H-2.31,  with 
a  cytotoxic titer of 1/~2  , produced  a  prolongation of 4.2  days,  whereas  D  end 274  IMMUNOGENICITY  AND ENHANCEABILITY  OF  H-2  ANTIGENS 
antibody AS-377,  anti-H-2.4,  with  a  cytotoxic titer  of }~2s,  produced  a  pro- 
longation of only 0.7 days. Also we have previously demonstrated enhancement 
with an anti-H-2.31  (K end)  with  a  dose as low as 0.1  /~1 (52).  It is of course 
possible  that  cytotoxic titers  are  a  poor measure  of the  concentration  of en- 
hancing antibody, but there is no direct evidence for this. At the moment there 
seems to be no good explanation of the relative enhanceability of grafts with an 
H-2K difference. 
SUMMARY 
The imnmnogenicity of single,  private H-2 specificities  has  been tested.  In 
most cases, the specificity was known to be confined either to H-2K or to H-2D. 
This  was  accomplished  by the  appropriate  choice,  as donor and  recipient,  or 
parent of the F1 hybrid recipient, of congenic strains differing at [t-2 only, and 
of recombinant haplotypes in donor and/or recipient. 
By nearly all tests,  the H-2K antigen appeared to be a stronger immunogen 
than  the II-2D antigen.  Skin  grafts with  an H-2K  difference showed median 
survival  times  (MST)  of 9.3-14.5  days; for H-2D the  values were  13.8-18.6. 
The difference was also present,  though narrowed, for second-set grafts. II-2K 
grafts regularly engendered a  demonstrable cytotoxic antibody response; with 
H-2D differences the response was absent or very weak. K  end cytotoxic titers 
after nmltiple immunizations with lymphoid tissues ranged from 1/t 2 to 1/6,048 , 
D end fiters from 0 to 1/~28. Hemagglutinafion titers showed no clear difference. 
The  results  of  passive  enhancement  of  skin  grafts  with  H-2  alloantibody 
produced in donor recipient  combinations,  identical  to those used for the skin 
grafts  showed  a  different  pattern.  H-2K,  despite  its  greater  immunogenic 
strength  was  more  easily  enhanced  than  H-2D.  Prolongation  of  MST's  for 
H-2K was 2.4-6.7 days, for H-2D grafts, 0.2-1.5 days. 
We gratefully acknowledge the excellent technical assistance of Miss Bernice Allito, Mrs. 
Harriet O'Connor of the Massachusetts General Hospital, and Mrs. Betty Holt and Mr. Frank 
Cunningham of the Jackson Laboratory. 
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